Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare ranibizumab injection to hemodilution at the early phase of Central Retinal Vein Occlusion (CRVO) and to determine if the combination of both treatments may have a synergic effect.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Intercommunal Creteil
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• CRVO confirmed by fluorescein angiography

• duration from onset of 1 month or less

• visual acuity of 20/32 or less

Exclusion Criteria:

• neovascular complication

• extensive retinal ischemia requiring prompt panretinal photocoagulation

• hematocrit level lower than 38%

• previous laser or surgery in the study eye, etc